Maxvax Biotechnology Limited Liability Company

This Phase 3 trial is testing a new RSV vaccine in 25,000 adults aged 60 and older. The goal is to see if a single shot can prevent lower respiratory tract disease caused by RSV. Participants are randomly assigned to receive either the vaccine or a placebo, and researchers will m…